- Home
- OCUL vs HROW Comparison
OCUL vs HROW Comparison
Compare OCUL & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCUL
- HROW
- Stock Information
- Founded
- OCUL 2006
- HROW 1998
- Country
- OCUL United States
- HROW United States
- Employees
- OCUL N/A
- HROW N/A
- Industry
- OCUL Biotechnology: Pharmaceutical Preparations
- HROW Biotechnology: Pharmaceutical Preparations
- Sector
- OCUL Health Care
- HROW Health Care
- Exchange
- OCUL Nasdaq
- HROW Nasdaq
- Market Cap
- OCUL 1.8B
- HROW 1.4B
- IPO Year
- OCUL 2014
- HROW N/A
- Fundamental
- Price
- OCUL $13.60
- HROW $36.99
- Analyst Decision
- OCUL Strong Buy
- HROW Strong Buy
- Analyst Count
- OCUL 6
- HROW 7
- Target Price
- OCUL $17.20
- HROW $64.67
- AVG Volume (30 Days)
- OCUL 2.2M
- HROW 671.8K
- Earning Date
- OCUL 08-05-2025
- HROW 08-11-2025
- Dividend Yield
- OCUL N/A
- HROW N/A
- EPS Growth
- OCUL N/A
- HROW N/A
- EPS
- OCUL N/A
- HROW N/A
- Revenue
- OCUL $56,664,000.00
- HROW $227,661,000.00
- Revenue This Year
- OCUL N/A
- HROW $45.86
- Revenue Next Year
- OCUL $18.87
- HROW $41.41
- P/E Ratio
- OCUL N/A
- HROW N/A
- Revenue Growth
- OCUL N/A
- HROW 47.69
- 52 Week Low
- OCUL $5.79
- HROW $20.85
- 52 Week High
- OCUL $13.82
- HROW $59.23
- Technical
- Relative Strength Index (RSI)
- OCUL 68.16
- HROW 51.26
- Support Level
- OCUL $12.41
- HROW $37.09
- Resistance Level
- OCUL $12.49
- HROW $40.41
- Average True Range (ATR)
- OCUL 0.56
- HROW 1.56
- MACD
- OCUL 0.04
- HROW -0.33
- Stochastic Oscillator
- OCUL 88.48
- HROW 28.60
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.